Market closed·Syncing…
Market closed · Close · 19 Nov

Symbiotec Pharmalab Limited SYMBIOTECshare price and chart

Symbiotec Pharmalab closed at ₹1,604.80 on 19 November 2026, down 1.02% on the day. The range since listing is ₹934.20 to ₹1,664.90.

₹1,604.80The price one share last traded at, in rupees.▼ 1.02% · ₹16.54
Low since listing ₹93492% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹1,665

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on SYMBIOTEC

Real prices, every charge counted. Pick one or write your own.

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
68Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
34.4%Near average
today 34.4%20d avg 33%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+28.7%1 monthHow much the share price has changed over the period.+32.8%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.70%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹10,312 Cr19 NovPrice to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.7.58xbooks of Sept 2026Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.00%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.24xbooks of Sept 2026

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 5 Nov 2026), sales was ₹280 cr and profit was ₹51.7 cr.

Worth watching
  • Promoters had pledged 38.5% of their shares at the end of September 2026, 12.83% of all shares.

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
33.28%promoter holding, as of 2026-09-30+0.0 pts since 2026
Promoter share since listing
2026-0833.28% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
33.3%
33.2%
29.8%
Promoter33.3%Foreign (FII)3.8%Domestic (DII)33.2%Public & others29.8%
Who is buying, who is leavingAug 26 to Sep 26
Promoter33.3%steady
Foreign (FII)3.8%-17.3 pts
Domestic (DII)33.2%+5.7 pts

Each line is that holder's share of all shares over the last 2 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.38.54%of promoter shares, as at 2026-09-30

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
General Updates17-Nov-2026

Symbiotec Pharmalab Limited has informed the Exchange about General Updates regarding 'Intimation regarding change in Corporate Identification Number and Listing Status of the Company'.

Analysts/Institutional Investor Meet/Con. Call Updates12-Nov-2026

Symbiotec Pharmalab Limited has informed the Exchange about Transcript

Analysts/Institutional Investor Meet/Con. Call Updates12-Nov-2026

Symbiotec Pharmalab Limited has informed the Exchange about Schedule of meet

Copy of Newspaper Publication06-Nov-2026

Symbiotec Pharmalab Limited has informed the Exchange about Copy of Newspaper Publication

Analysts/Institutional Investor Meet/Con. Call Updates06-Nov-2026

Symbiotec Pharmalab Limited has informed the Exchange about Link of Recording

General Updates06-Nov-2026

Symbiotec Pharmalab Limited has informed the Exchange about General Updates ((Symbiotec Signs 10-Year Take-Or-Pay Agreement To Manufacture Fermentation-Based Alternative Protein For EU Innovator))

Monitoring Agency Report05-Nov-2026

The Monitoring Agency Report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the Initial Public Offer (IPO) of the Company for the quarter year ended September 30, 2026

Press Release05-Nov-2026

Symbiotec Pharmalab Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Investor Release being issued by the Company for the Quarter and half year ended September 30, 2026".

Investor Presentation05-Nov-2026

Symbiotec Pharmalab Limited has informed the Exchange about Investor Presentation

Outcome of Board Meeting05-Nov-2026

Symbiotec Pharmalab Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Analysts/Institutional Investor Meet/Con. Call Updates28-Oct-2026

Symbiotec Pharmalab Limited has informed the Exchange about Schedule of meet

Certificate under SEBI (Depositories and Participants) Regulations, 201805-Oct-2026

Symbiotec Pharmalab Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026

General Updates30-Sep-2026

Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategiccommercialization agreement with a leading global pharmaceutical company forDual Chamber Vial ('DCV') products in the U.S.

General Updates30-Sep-2026

Symbiotec Pharmalab Limited has informed the Exchange about General Updates

Trading Window29-Sep-2026

Symbiotec Pharmalab Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Backtest idea · SYMBIOTECMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on SYMBIOTEC
Backtest idea · SYMBIOTECLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on SYMBIOTEC
Backtest idea · SYMBIOTECSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on SYMBIOTEC
Your own ideaWrite a rule for SYMBIOTEC in plain English“Buy SYMBIOTEC when …”
Start writing
Buy the dip on SYMBIOTECBuy when RSI(14) drops below 30
52-week high breakout on SYMBIOTECBuy when closes at a 52-week high
Golden cross on SYMBIOTECBuy when 50-day EMA crosses above 200-day
Stochastic oversold on SYMBIOTECBuy when stochastic %K drops below 20
Pullback in an uptrend on SYMBIOTECBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹10,312 cr
Larger than 70% of 141 peers
sector middle ₹2,189 cr
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
7.6x
Higher than 86% of 125 peers
sector middle 3.6x
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.24
Higher than 56% of 125 peers
sector middle 0.19
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
Lower than 56% of 141 peers
sector middle 0.1%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Backtest idea · SYMBIOTECStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on SYMBIOTEC
Backtest idea · SYMBIOTECPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on SYMBIOTEC
Backtest idea · SYMBIOTECBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on SYMBIOTEC
Backtest idea · SYMBIOTEC52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on SYMBIOTEC
Backtest idea · SYMBIOTECGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on SYMBIOTEC
MACD momentum on SYMBIOTECBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on SYMBIOTECBuy when closes below the lower Bollinger band
Supertrend rider on SYMBIOTECBuy when supertrend turns up
Buy the dip on SYMBIOTECBuy when RSI(14) drops below 30
52-week high breakout on SYMBIOTECBuy when closes at a 52-week high

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
·
·
·
·
·
·
·
·
·
+5.9
+28.8
·
+36.4%
2m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2026-09-02JUNOMONETA FINSOL PRIVATE LIMITED · bulkBUY3,57,516₹1,123.40₹40.16 Cr
2026-09-02JUNOMONETA FINSOL PRIVATE LIMITED · bulkSELL3,57,516₹1,123.68₹40.17 Cr
2026-09-01JUNOMONETA FINSOL PRIVATE LIMITED · bulkBUY18,76,359₹1,068.22₹200.44 Cr
2026-09-01JUNOMONETA FINSOL PRIVATE LIMITED · bulkSELL18,47,308₹1,066.89₹197.09 Cr
2026-09-01IRAGE BROKING SERVICES LLP · bulkSELL9,28,711₹1,057.96₹98.25 Cr
2026-09-01NK SECURITIES RESEARCH PRIVATE LIMITED · bulkBUY8,42,160₹1,063.42₹89.56 Cr
2026-09-01NK SECURITIES RESEARCH PRIVATE LIMITED · bulkSELL8,42,160₹1,063.88₹89.60 Cr
2026-09-01IRAGE BROKING SERVICES LLP · bulkBUY7,52,199₹1,079.32₹81.19 Cr

Read enough? Test SYMBIOTEC. “Buy SYMBIOTEC when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free